Discovery of DNL343: a potent, selective, and brain-penetrant eIF2B activator designed for the treatment of neurodegenerative diseases - Denali Therapeutics

Investors & News
Contact Us

Medical Professionals

03/21/2024

Share

Science

TransportVehicle™ Platform
Publications
Partnerships & Collaborations

Pipeline

Pipeline

Patients

Our Commitment
Advocacy
Grants & Sponsorships
Therapeutic Areas
Clinical Studies
Early Access Policy

Medical Professionals

Get in Touch
Clinical Studies
Recent Publications
Grants & Sponsorships
Early Access Policy

About Us

About Us
Leadership
Investors & News
Contact Us

Careers

Life at Denali
Benefits & Offerings
Internships
Postdoc Program
STEM Outreach

Legal

Privacy Policy
Terms of Use
Consumer Health Data Privacy Policy
Cookies Policy

© 2026 Denali Therapeutics